BORTEZOMIB EG 2.5 mg/ml, solution for injection bottle, 1.4 ml
Active ingredients: Bortezomib, ESTER BORONIQUE DE MANNITOL
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 1.4 mlintraveineuse;sous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BORTEZOMIB EG 2,5 mg/ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intraveineuse;sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 1,4 mL
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 2 Mar 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67671540CIP73015068CIP133400930150689Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ESTER BORONIQUE DE MANNITOLsolution | — | SA |
| BORTÉZOMIBsolution | 2,5 mg · 1 mL de solution | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.